Abilita Therapeutics and Finnish Orion Corporation just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Abilita Therapeutics and Finnish Orion Corporation, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Abilita Therapeutics and Orion Announce Research Collaboration to Develop Next-Generation Antibody Therapeutics in Oncology and Pain Areas
Contract Type
partnership
San DiegoBiotechnologyTherapeuticsDescription
Abilita Therapeutics, Inc. and Finnish Orion Corporation have entered into a collaboration to leverage Abilita's pioneering EMP™ antibody discovery platform for challenging multi-span membrane protein (MMP) targets, with a focus on oncology and pain. Orion has an option to license an undisclosed Abilita discovery program and select two additional MMP targets for drug discovery over the collaboration period. Abilita has the potential to earn up to $785 million plus royalties on commercial sales